Skip to content

Study · Non-randomized trial · n = 46 · 1996

15 results

Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.

de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E

The Journal of clinical endocrinology and metabolism1 Apr 1996Cited by 77 (Europe PMC)

PMID8636336 (opens in a new tab)DOI10.1210/jcem.81.4.8636336 (opens in a new tab)PepBankPUB-08636336
Source linkPubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In GH-deficient men, side effects required GH dose reduction in 18 of 46 patients.

    In plain wordsIn GH-deficient men, side effects required GH dose reduction in 18 of 46 patients.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDose reduction due to side effects
    Study

    n = 46

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.33-3.0 IU/m(2)-day · 1 yrAs given in this study (human).

    Measurements

    Patients requiring dose reduction
    18 patients
    46 patients

    Source sentences

    Summary
    During GH treatment, dose reduction was necessary because of side-effects in 18 of 46 patients,
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-treated GH-deficient men, 2 of 46 developed IGFBP-3 above the upper normal limit.

    In plain wordsIn GH-treated GH-deficient men, 2 of 46 developed IGFBP-3 above normal.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePatients with elevated IGFBP-3
    Study

    n = 46

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.33-3.0 IU/m(2)-day · 1 yrAs given in this study (human).

    Measurements

    Elevated IGFBP-3
    2 patients
    46 patients

    Source sentences

    Summary
    The number of patients who developed IGFBP-3 or ALS levels that exceeded the upper normal limit was substantially smaller than the number of patients with elevated IGF-I concentrations (2, 8, and 19 of 46 patients, respectively).
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-treated GH-deficient men, 8 of 46 developed ALS above the upper normal limit.

    In plain wordsIn GH-treated GH-deficient men, 8 of 46 developed ALS above normal.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePatients with elevated ALS
    Study

    n = 46

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.33-3.0 IU/m(2)-day · 1 yrAs given in this study (human).

    Measurements

    Elevated ALS
    8 patients
    46 patients

    Source sentences

    Summary
    The number of patients who developed IGFBP-3 or ALS levels that exceeded the upper normal limit was substantially smaller than the number of patients with elevated IGF-I concentrations (2, 8, and 19 of 46 patients, respectively).
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-treated GH-deficient men, 19 of 46 developed elevated IGF-I concentrations.

    In plain wordsIn GH-treated GH-deficient men, 19 of 46 developed elevated IGF-I.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePatients with elevated IGF-I
    Study

    n = 46

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.33-3.0 IU/m(2)-day · 1 yrAs given in this study (human).

    Measurements

    Elevated IGF-I
    19 patients
    46 patients

    Source sentences

    Summary
    The number of patients who developed IGFBP-3 or ALS levels that exceeded the upper normal limit was substantially smaller than the number of patients with elevated IGF-I concentrations (2, 8, and 19 of 46 patients, respectively).
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  5. 05HumanNon-randomized trialSafety outcome

    In GH-deficient men receiving a maintenance GH dose of 1 IU/M(2)-day, 18% required dose reduction because of side effects.

    In plain wordsIn GH-deficient men receiving 1 IU/M(2)-day of GH, side effects required dose reduction in 18%.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDose reduction at maintenance dose
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    1 IU/M(2)-day · 1 yrAs given in this study (human).

    Measurements

    Dose reduction
    18%
    1 IU/M(2)-day

    Source sentences

    Summary
    During GH treatment, dose reduction was necessary because of side-effects in 18 of 46 patients, i.e. in 18% of the patients receiving a maintenance dose of 1 IU/M(2)-day,
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  6. 06HumanNon-randomized trialSafety outcome

    In GH-deficient men receiving 2 IU/m(2)-day of GH, 35% required dose reduction because of side effects.

    In plain wordsIn GH-deficient men receiving 2 IU/m(2)-day of GH, side effects required dose reduction in 35%.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDose reduction at maintenance dose
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    2 IU/m(2)-day · 1 yrAs given in this study (human).

    Measurements

    Dose reduction
    35%
    2 IU/m(2)-day

    Source sentences

    Summary
    in 35% of the patients receiving a dose of 2 IU/m(2)-day,
    3 context sentences
    Summary · context
    During GH treatment, dose reduction was necessary because of side-effects in 18 of 46 patients,
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  7. 07HumanNon-randomized trialSafety outcome

    In GH-deficient men receiving 3 IU/M(2)-day of GH, 67% required dose reduction because of side effects.

    In plain wordsIn GH-deficient men receiving 3 IU/M(2)-day of GH, side effects required dose reduction in 67%.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDose reduction at maintenance dose
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 IU/M(2)-day · 1 yrAs given in this study (human).

    Measurements

    Dose reduction
    67%
    3 IU/M(2)-day

    Source sentences

    Summary
    and in 67% of the patients receiving a dose of 3 IU/M(2)-day.
    3 context sentences
    Summary · context
    During GH treatment, dose reduction was necessary because of side-effects in 18 of 46 patients,
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  8. 08HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, the rise in serum IGF-I, IGFBP-3 and ALS during the first month of GH treatment was dose dependent.

    In plain wordsIn GH-deficient men, the rise in IGF-I, IGFBP-3 and ALS during the first month of GH treatment depended on the GH dose.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseDose-dependent serum marker rise
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.33-3.0 IU/m(2)-day · first monthAs given in this study (human).

    Source sentences

    Summary
    The rise in serum marker concentrations during the first month of treatment was dose dependent.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  9. 09HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, IGF-I, IGFBP-3, and ALS increased significantly with GH doses as low as 0.33 IU/M(2)-day.

    In plain wordsIn GH-deficient men, IGF-I, IGFBP-3, and ALS increased with GH doses as low as 0.33 IU/M(2)-day.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I, IGFBP-3, and ALS increases at low dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.33 IU/M(2)-day · 1 yrAs given in this study (human).

    Source sentences

    Summary
    Significant increases in IGF-I, IGFBP-3, and ALS levels were observed with a dose as low as 0.33 IU/M(2)-day.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  10. 10HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, the minimum GH dose needed to normalize serum IGF-I was 0.66 IU/M(2)-day.

    In plain wordsIn GH-deficient men, serum IGF-I normalized with a minimum GH dose of 0.66 IU/M(2)-day.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableMinimum dose for IGF-I normalization
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.66 IU/M(2)-day · 1 yrAs given in this study (human).

    Measurements

    Minimal GH dose for IGF-I normalization
    0.66 IU/M(2)-day
    serum IGF-I

    Source sentences

    Summary
    The minimal GH dose required for normalization of the serum IGF-I concentration was 0.66 IU/M(2)-day, and it was 1.0 IU/M(2)-day for ALS and IGFBP-3.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  11. 11HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, the minimum GH dose needed to normalize serum ALS was 1.0 IU/M(2)-day.

    In plain wordsIn GH-deficient men, serum ALS normalized with a minimum GH dose of 1.0 IU/M(2)-day.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableMinimum dose for ALS normalization
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.0 IU/M(2)-day · 1 yrAs given in this study (human).

    Measurements

    Minimal GH dose for ALS normalization
    1 IU/M(2)-day
    serum ALS

    Source sentences

    Summary
    The minimal GH dose required for normalization of the serum IGF-I concentration was 0.66 IU/M(2)-day, and it was 1.0 IU/M(2)-day for ALS and IGFBP-3.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  12. 12HumanNon-randomized trialEfficacy outcome

    In GH-deficient men, the minimum GH dose needed to normalize serum IGFBP-3 was 1.0 IU/M(2)-day.

    In plain wordsIn GH-deficient men, serum IGFBP-3 normalized with a minimum GH dose of 1.0 IU/M(2)-day.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableMinimum dose for IGFBP-3 normalization
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.0 IU/M(2)-day · 1 yrAs given in this study (human).

    Measurements

    Minimal GH dose for IGFBP-3 normalization
    1 IU/M(2)-day
    serum IGFBP-3

    Source sentences

    Summary
    The minimal GH dose required for normalization of the serum IGF-I concentration was 0.66 IU/M(2)-day, and it was 1.0 IU/M(2)-day for ALS and IGFBP-3.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  13. 13HumanNon-randomized trialEfficacy outcome

    In GH-deficient men receiving 2.0 IU/M(2)-day of GH, mean serum IGF-I rose above normal.

    In plain wordsIn GH-deficient men receiving 2.0 IU/M(2)-day of GH, average serum IGF-I rose above normal.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAbnormally high mean IGF-I
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 IU/M(2)-day · 1 yrAs given in this study (human).

    Source sentences

    Summary
    In patients receiving 2.0 IU/M(2)-day, the mean serum IGF-I concentration rose to an abnormally high level, whereas at this dose, the mean IGFBP-3 and ALS levels were not different from normal.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  14. 14HumanNon-randomized trialEfficacy outcome

    In GH-deficient men receiving 2.0 IU/M(2)-day of GH, mean IGFBP-3 did not differ from normal.

    In plain wordsIn GH-deficient men receiving 2.0 IU/M(2)-day of GH, average IGFBP-3 did not differ from normal.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeMean IGFBP-3 versus normal
    Study

    n: not reported in source

    Comparator
    Normal levels
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 IU/M(2)-day · 1 yrAs given in this study (human).

    Source sentences

    Summary
    In patients receiving 2.0 IU/M(2)-day, the mean serum IGF-I concentration rose to an abnormally high level, whereas at this dose, the mean IGFBP-3 and ALS levels were not different from normal.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.
  15. 15HumanNon-randomized trialEfficacy outcome

    In GH-deficient men receiving 2.0 IU/M(2)-day of GH, mean ALS did not differ from normal.

    In plain wordsIn GH-deficient men receiving 2.0 IU/M(2)-day of GH, average ALS did not differ from normal.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeMean ALS versus normal
    Study

    n: not reported in source

    Comparator
    Normal levels
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2.0 IU/M(2)-day · 1 yrAs given in this study (human).

    Source sentences

    Summary
    In patients receiving 2.0 IU/M(2)-day, the mean serum IGF-I concentration rose to an abnormally high level, whereas at this dose, the mean IGFBP-3 and ALS levels were not different from normal.
    2 context sentences
    Summary · context
    Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study.
    Summary · context
    The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.